Portola begins Phase III trial of antidote for Factor Xa inhibitor

03/19/2014 | American City Business Journals

Portola Pharmaceuticals will begin the first of multiple small Phase III trials of its Factor Xa inhibitor antidote andexanet alfa, or PRT-4445, the only universal antidote currently in clinical development. The study will evaluate the safety and efficacy of andexanet alfa with Bristol-Myers Squibb and Pfizer's apixaban, or Eliquis. Portola has several small late-stage trials planned for the experimental blood thinner antidote and various inhibitors.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC